More tools:Markets·Screener·Research·Chat

QTREX QUANTUM LTD (QTEX) Financial Statements

QTREX QUANTUM LTD
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG00ZKH0QD0
US
0.85▼ 1.16 (-57.72%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close2.01
Day's Range1.99 – 2.52
52-Week Range0.28 – 3.85
Volume45.6M
Avg Volume81.9M
Share Statistics
Shares Outstanding
Employees—
ExchangeUS
Listed—
Share count as of December 31, 2025
Loading Income Statement…
Key questions about QTREX QUANTUM LTD (QTEX)
What is QTREX QUANTUM LTD's Market Cap?
QTREX QUANTUM LTD's Market Cap is $30.5M, based on as-reported figures from SEC (XBRL) filings.
What is QTREX QUANTUM LTD's Price / Sales?
QTREX QUANTUM LTD's Price / Sales is 105.7×, based on as-reported figures from SEC (XBRL) filings.
What is QTREX QUANTUM LTD's Revenue (TTM)?
QTREX QUANTUM LTD's Revenue (TTM) is $289.0K, based on as-reported figures from SEC (XBRL) filings.
What is QTREX QUANTUM LTD's Net Income (TTM)?
QTREX QUANTUM LTD's Net Income (TTM) is -$13.2M, based on as-reported figures from SEC (XBRL) filings.
What is QTREX QUANTUM LTD's EBITDA?
QTREX QUANTUM LTD's EBITDA is -$13.5M, based on as-reported figures from SEC (XBRL) filings.
What is QTREX QUANTUM LTD's Diluted EPS (TTM)?
QTREX QUANTUM LTD's Diluted EPS (TTM) is -0.37, based on as-reported figures from SEC (XBRL) filings.
What is QTREX QUANTUM LTD's EBITDA Margin?
QTREX QUANTUM LTD's EBITDA Margin is -4661.9%, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Revenues
Cost of revenues
Gross Profit
% of revenue0.7%
Research and development expenses
General and administrative expenses
Sales and marketing expenses
Other expenses
Operating loss
% of revenue4713.8%
Interest income from deposits
Finance expenses (income), net
Loss before tax
Taxes on income
Total comprehensive and net loss
% of revenue4574.4%
Net loss per ordinary share, basic (in Dollars per share)
Net loss per ordinary share, diluted (in Dollars per share)